BP InnoMed Limited
HKBU encompasses eight Faculties/Schools offering a range of undergraduate programmes, associate degrees and higher diploma programmes as well as taught postgraduate programmes and research postgraduate programmes leading to the award of master and doctoral degrees. It prides itself on its dual focus on teaching and research and encourages service to society among its staff and students. One of the area of strengths at HKBU is in health and wellness, where we have a world-leading School of Chinese Medicine and Pharmacology.
At TechInnovation 2021, we are presenting a series of innovations and solutions for the betterment of your health and wellness.
Our Technology Offers
Novel Anti-Viral Targeted Drug for Nasopharyngeal Cancer Treatment
EBV is a ubiquitous human herpes virus, which spreads through saliva. EBV infects over 90% of the human population and can establish life-long persistence in the host. Most people get EBV when they are young, but they will not experience any symptoms until they get older.
There are about 200,000 EBV-associated cancer new cases per year. Nasopharyngeal cancer (NPC) is one of EBV associated cancers which is endemic in a few areas including Southern China, Southeast Asia, North Africa and the Arctic. The highest NPC incidence rate is found in Southern China including Hong Kong. The association of NPC and EBV is nearly 100% in endemic areas. Unfortunately, more than 80% of the new NPC cases are diagnosed in stage III or IV, while the survival rate of stage IV NPC is only 38%. Early detection and treatment would help to increase survival rate.
This invention is a new EBV-specific targeted agent which selectively kills cancer cells without affecting any normal cells. The uptake of this drug can also be traced by the fluorescent signal that can be used for cancer cells imaging.
Currently, there is no single agent that can both image and kill NPC cancer cells at the same time.